Trump Pledges To Free Silk Road Drug Market Operator Russ Ulbricht, Despite Calling For Execution Of Drug Sellers
Biden’s Reelection Strategy Is To ‘Get More People To Smoke Marijuana,’ GOP Senator Claims
DEA Says ‘THCA Does Not Meet The Definition’ Of Legal Hemp As Congress Weighs Cannabinoid Recriminalization In Farm Bill
Top New York Marijuana Regulator Resigns Following Governor’s Criticism
Massachusetts Marijuana Delivery Rule Requiring Two Drivers Per Vehicle Remains In Force Despite Vote To Repeal It
Federal Health Agency Acknowledges Psilocybin’s Therapeutic Potential And Touts Forthcoming Psychedelic Research
Cannabis Use Before Bedtime Does Not Cause Next-Day Impairment Of Cognitive Ability Or Driving Performance, Study Shows
Marijuana Use Linked To Increase In Light Physical Activity, Study Challenging ‘Lazy Stoner’ Stereotype Finds
Psychedelic Mushrooms Won’t Make You Believe In God, But They Might Make You Think Robots Are Conscious, Study Finds
Cannabis Can Help Treat Female Orgasmic Disorder, Study Finds As Ohio Officials Consider Adding It As Qualifying Condition
Brands And Advocacy Groups—From ACLU To KFC—Launch 4/20 Promotions To Mark The Marijuana Holiday
Former Minnesota Gov. Jesse Ventura Promotes New Cannabis Brand Ahead Of 4/20 That He’d ‘Offer To You’ On Governor’s Mansion Visit
Colorado Amendment Addresses Concerns On Banning Social Media Marijuana Posts, But Questions On Psychedelics And Other Drugs Remain
Former Minnesota Governor Jesse Ventura Launches His Own Cannabis Brand, Fulfilling A ‘Lifelong Dream’
Marijuana Rolling Paper Company Seeks Content Creator To ‘Get Paid To Smoke Weed’ For $70,420 Salary
States Have Generated Over $20 Billion In Marijuana Tax Revenue Since First Markets Opened, New Report Finds
Arkansas Medical Marijuana Dispensary Gets License Revoked Over Alleged Violations
New Jersey Set A New Marijuana Sales Record Last Quarter, With Regulators Touting ‘Historical Highs’ On 4/20 Weekend
Massachusetts Saw Record-Breaking Marijuana Sales On 4/20, Pushing State Across $6 Billion Mark For Recreational Purchases
Legal Marijuana Purchases In Michigan Spiked In March, Reaching A New Record High
Trump Pledges To Free Silk Road Drug Market Operator Russ Ulbricht, Despite Calling For Execution Of Drug Sellers
Top Federal Drug Official Says There’s ‘Tremendous Excitement’ Around Psychedelic Medicine, But ‘It’s Not Magic’
New Hampshire Senate Passes Amended Marijuana Legalization Bill, But Key House Lawmakers Don’t Like Recent Changes
House Committee Approves Farm Bill Amendment To Ban Most Hemp-Derived Cannabinoid Products Like Delta-8 THC
Ted Cruz Suggests Marijuana Rescheduling Might Lead To More People Dying In Car Crashes From Impaired Driving
NH legal cannabis bill heads to final vote (Newsletter: May 27, 2024)
Military couldn’t test recruits for cannabis under approved bill (Newsletter: May 24, 2024)
Fed cannabis lawsuit arguments (Newsletter: May 23, 2024)
Feds accept cannabis rescheduling comments (Newsletter: May 22, 2024)
DOJ weighs cannabis economic impact of rescheduling (Newsletter: May 21, 2024)
Published
on
By
A newly posted page about psilocybin on a federal health agency’s website acknowledges the potential benefits the psychedelic substance might provide—including for treatment of alcohol use disorder, anxiety and depression. The page also highlights psilocybin research being funded by the federal government into the drug’s effects on pain, migraines, psychiatric disorders and various other conditions.
The page, “Psilocybin for Mental Health and Addiction: What You Need To Know,” was posted this month on the website of the National Center for Complementary and Integrative Health (NCCIH), which is part of the National Institutes of Health.
It includes basic information about what psilocybin is, where it comes from, the legal status of the drug and preliminary findings around safety and efficacy.
Though psilocybin remains a Schedule I controlled substance, the page notes, it’s been granted “breakthrough therapy” status by the Food and Drug Administration (FDA) and “has been either decriminalized or deprioritized in some states and the District of Columbia.”
“The legal status in the United States of psychedelic drugs including psilocybin continues to evolve.”
In terms of potential benefits, the NCCIH page highlights three possible areas of application: alcohol use disorder, anxiety and existential distress and depression.
It highlights a 2022 study that “suggested that psilocybin may be helpful for alcohol use disorder.” That research found people who were in psilocybin-assisted therapy had fewer heavy-drinking days over 32 weeks than the control group, which the NCCIH page says “suggests that psilocybin may be helpful for alcohol use disorder.”
As for anxiety and existential distress, the page says a “small amount” of research has studied psilocybin as a treatment for distress in people with serious medical illnesses, like advanced cancer.
“A 2020 analysis of 4 small studies in 117 people, most with life-threatening cancer, concluded that psilocybin combined with psychotherapy may be safe and effective for improving anxiety, depression, and existential distress, as well as quality of life,” it says, adding that “Because of limitations in the design of the studies and the small number and health status of the people involved, the authors note that the conclusions may have been biased.”
Regarding depression, a “growing body of research has suggested that psilocybin combined with psychotherapy may be helpful for depression in the short and medium term,” the page says, citing three separate studies.
A 2023 review and meta-analysis found that psilocybin-assisted therapy “reduced depression symptoms for up to 5 weeks,” while a separate study that year found that a single dose of psilocybin combined with therapy “rapidly reduced symptoms of depression within 8 days, with benefits lasting for 6 weeks.”
Other research, from 2021, found that psilocybin-assisted therapy “did not reduce symptoms better” than a common antidepressant medication combined with psychotherapy.
The NCCIH page reminds readers to not use psilocybin “to postpone seeing a health care provider about a medical and mental health problem” and encourages people to “take charge of your health—talk with your health care providers about any complementary health approaches you use.”
One promising application for psychedelics could be pain management. NCCIH notes on its psilocybin page that the agency is currently funding research to study the safety and efficacy of psychedelic-assisted therapy for chronic pain, while other federally funded research is looking into “the effect of psilocybin on people with chronic low-back pain and depression in regard to their emotions and perceptions of pain.”
Other inquiries seek to better understand the chemistry of psilocybin and the possible risk of interactions with selective serotonin reuptake inhibitors (SSRIs), commonly used to treat psychiatric disorders, migraine headaches and certain types of pain, the NCCIH page says.
Separate research published this month on psilocybin found that it’s unlikely that a single experience with the drug changes people’s religious or metaphysical beliefs—though it may affect their perception of whether animals, plants or other objects experience consciousness.
Findings of another recent study suggests that the use of full-spectrum psychedelic mushroom extract has a more powerful effect than chemically synthesized psilocybin alone, which could have implications for psychedelic-assisted therapy. The findings imply that the experience of entheogenic mushrooms may involve a so-called “entourage effect” similar to what’s observed with cannabis and its many components.
A separate study recently published by the American Medical Association found that single-dose psilocybin use was “not associated with risk of paranoia,” while other adverse effects such as headaches are generally “tolerable and resolved within 48 hours.”
That study, published in JAMA Psychiatry, involved a meta-analysis of double-blind clinical trials where psilocybin was used to treat anxiety and depression from 1966 to last year.
AMA published another recent study that similarly contradicted commonly held beliefs about the potential risks of psychedelics use, finding the substances “may be associated with lower rates of psychotic symptoms among adolescents.”
Also, results of a clinical trial published by AMA in December “suggest efficacy and safety” of psilocybin-assisted psychotherapy for treatment of bipolar II disorder, a mental health condition often associated with debilitating and difficult-to-treat depressive episodes.
The association also published research last August that found people with major depression experienced “clinically significant sustained reduction” in their symptoms after just one dose of psilocybin.
Top VA Official Says Psychedelics Have “Surpassed” Marijuana In Bipartisan Acceptance In Congress
Photo courtesy of Wikimedia/Mädi.
Cannabis Use Before Bedtime Does Not Cause Next-Day Impairment Of Cognitive Ability Or Driving Performance, Study Shows
Ben Adlin, a senior editor at Marijuana Moment, has been covering cannabis and other drug policy issues professionally since 2011. He was previously a senior news editor at Leafly, an associate editor at the Los Angeles Daily Journal and a Coro Fellow in Public Affairs. He lives in Washington State.
Trump Pledges To Free Silk Road Drug Market Operator Russ Ulbricht, Despite Calling For Execution Of Drug Sellers
Biden’s Reelection Strategy Is To ‘Get More People To Smoke Marijuana,’ GOP Senator Claims
DEA Says ‘THCA Does Not Meet The Definition’ Of Legal Hemp As Congress Weighs Cannabinoid Recriminalization In Farm Bill
NH legal cannabis bill heads to final vote (Newsletter: May 27, 2024)
Top New York Marijuana Regulator Resigns Following Governor’s Criticism
Massachusetts Marijuana Delivery Rule Requiring Two Drivers Per Vehicle Remains In Force Despite Vote To Repeal It
All the cannabis news you need, all in one place. Copyright © 2017-2024 Marijuana Moment LLC ® and Tom Angell
Federal Health Agency Acknowledges Psilocybin's Therapeutic Potential And Touts Forthcoming Psychedelic Research – Marijuana Moment
